(PQ1) HIV-infected T-cell exosomes in lung cancer progression
(PQ1) HIV 感染的 T 细胞外泌体在肺癌进展中的作用
基本信息
- 批准号:10202519
- 负责人:
- 金额:$ 75.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AIDS/HIV problemAcquired Immunodeficiency SyndromeAdjuvantAgeAgingAllograftingAutomobile DrivingBenignBloodBlood CirculationBody FluidsBone MarrowBone Marrow CellsBone Marrow TransplantationCancer ModelCancer PatientCancer cell lineCell NucleusCell ProliferationCellsCessation of lifeDataDevelopmentDiagnosisDistantEndocytic VesicleEndosomesEpidermal Growth Factor ReceptorEpithelial CellsFVB MouseFoundationsGeneral PopulationGenetically Engineered MouseGrowthHIVHIV InfectionsHIV SeropositivityHIV-1HumanImmuneImmunologicsIn VitroIndividualKRASG12DLeadLightLiposomesLongevityLungMAPK3 geneMEKsMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of lungMapsMediatingMembrane ProteinsMethodsMitogen-Activated Protein KinasesModelingMolecularMusNeoplasm MetastasisPatientsPersonsPhosphorylationPlasmaPopulationPreventionProductionPrognosisProteomeProto-OncogenesPublishingRNARas/RafRelative RisksResearchResponse ElementsRiskRisk FactorsRoleSignal TransductionSiteSon of Sevenless ProteinsSpecimenT-LymphocyteTLR3 geneTestingTherapeutic InterventionTransactivationTransgenic MiceTumor TissueTumor stageUrethaneantiretroviral therapyaptamercancer cellcancer specimen resourcecell motilitychemical carcinogenexosomeextracellular vesiclesin vivoinhibitor/antagonistintercellular communicationlung allograftlung cancer celllung tumorigenesismigrationmouse modelnovelnovel strategiespatient derived xenograft modelreconstitutionresponsesuccesstransplant modeltrendtumor progressiontumorigenesis
项目摘要
Project Summary/Abstract
Lung cancer (LCa) is the second most common malignancy in the US with about 222,500 new cases and
155,900 deaths each year. HIV-infected individuals and AIDS patients have increased relative risk of LCa by
250% after controlling for other potential risk factors. LCa in HIV+ people under antiretroviral therapy (ART) is
diagnosed at younger ages than those in the general population. This trend in the ART era is implicitly
attributed to prolonged life span and aging of the population. The success of new approaches to control lung
tumorigenesis in the population is contingent to identify HIV-specific mechanisms that facilitate the tumor
progression and metastasis. HIV-infected T cells release a variety of immunologically active exosomes, small
vesicles of endocytic origin, to influence intercellular communication and material transfer at both local and
distant sites, thus potentially contribute to enhanced risk for tumorigenesis. Our preliminary studies have found
that exosomes secreted by HIV-infected T cells and purified from the blood of lung cancer patients of people
living with HIV (PLWH) significantly stimulated lung cancer cell proliferation. HIV-associated exosomes induced
MAP kinase ERK1/2 activation via interaction with epidermal growth factor receptor (EGFR) and the toll like
receptor 3 (TLR3). Mechanistically, the HIV trans-activation response (TAR) element RNA, which exists in
excess of other HIV RNAs in exosome from HIV-infected T cells, is responsible for enhanced cancer cell
proliferation and proto-oncogene expression. We have established a bone marrow transplant (BMT) mouse
model in which lethally-irradiated FVB mice were grafted with syngeneic bone marrow cells of Tg26 HIV-
transgenic mice. Growth and metastasis of allografts LCa cells were significantly enhanced in grafted mice
containing HIV+ bone marrow cells compared with that in non-grafted control mice. However, reconstitution of
circulating immune cells and bone marrow remained the same between two groups of mice, suggesting that
TAR RNA-bearing exosomes from reconstituted HIV+ immune cells may promote LCa progression in the BMT
model. Taken together, these data lead us to hypothesize that TAR RNA-bearing exosomes from HIV-infected
immune cells promote lung cancer growth and progression and that controlling release of the exosomes or
directly targeting the TAR RNA may serve as an adjuvant for prevention and treatment of lung cancer in HIV-
infected individuals. To test this hypothesis, we will first delineate the mechanism by which HIV-1-infected T-
cell exosomes stimulate LCa growth and progression in vivo using the BMT model. The potentials for
therapeutic intervention of LCa promotion by HIV will be examined through inhibition of exosome production
and neutralization of TAR RNA. Finally, we will comprehensively examine the HIV-positive exosomal
membrane proteins for interaction with EGFR and HIV-specific cargo components in the circulation using our
novel EV-omics approach. Completion of the proposed studies will shed light on the mechanisms underlying
HIV-mediated promotion of LCa and lay a foundation for therapeutic intervention of non-AIDS-defining cancers.
项目总结/摘要
肺癌(LCa)是美国第二常见的恶性肿瘤,约有222,500例新发病例,
每年有155,900人死亡。HIV感染者和AIDS患者LCa的相对风险增加,
在控制其他潜在风险因素后,250%。接受抗逆转录病毒治疗(ART)的艾滋病毒阳性者的LCa是
在比一般人群更年轻的年龄诊断。ART时代的这一趋势,
这是由于寿命延长和人口老龄化。控制肺部疾病新方法的成功
人群中的肿瘤发生取决于确定HIV特异性机制,
进展和转移。HIV感染的T细胞释放出多种免疫活性外泌体,
胞吞起源的囊泡,以影响局部和局部的细胞间通讯和物质转移,
远距离的位点,因此可能有助于增加肿瘤发生的风险。我们的初步研究发现
由HIV感染的T细胞分泌并从肺癌患者的血液中纯化的外泌体
艾滋病病毒携带者(PLWH)显著刺激肺癌细胞增殖。HIV相关外泌体诱导
MAP激酶ERK 1/2通过与表皮生长因子受体(EGFR)等相互作用激活
受体3(TLR 3)。从机制上讲,HIV反式激活反应(TAR)元件RNA,存在于
来自HIV感染的T细胞的外泌体中过量的其他HIV RNA,负责增强癌细胞
增殖和原癌基因表达。我们建立了一个骨髓移植(BMT)小鼠
将致死剂量照射的FVB小鼠移植入Tg 26 HIV-的同基因骨髓细胞的模型
转基因小鼠LCa细胞在移植小鼠体内的生长和转移能力明显增强
含有HIV+骨髓细胞的小鼠与未移植的对照小鼠相比。然而,重建
循环免疫细胞和骨髓在两组小鼠之间保持相同,这表明,
来自重建的HIV+免疫细胞的携带TAR RNA的外泌体可能促进BMT中的LCa进展
模型总之,这些数据使我们假设来自HIV感染者的携带TAR RNA的外泌体,
免疫细胞促进肺癌生长和进展以及外泌体或
直接靶向TAR RNA可作为预防和治疗HIV-1感染者肺癌的佐剂。
感染的人。为了验证这一假设,我们将首先描述HIV-1感染T细胞的机制,
细胞外泌体使用BMT模型在体内刺激LCa生长和进展。的潜能
将通过抑制外泌体的产生来检查HIV促进LCa的治疗性干预
和TAR RNA的中和。最后,我们将全面检查HIV阳性外泌体,
使用我们的方法,研究了在循环中与EGFR和HIV特异性货物组分相互作用的膜蛋白。
新的EV组学方法。完成拟议的研究将有助于了解其背后的机制
HIV介导的LCa的促进作用,为非AIDS定义的癌症的治疗性干预奠定基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ge Jin其他文献
Ge Jin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ge Jin', 18)}}的其他基金
(PQ1) HIV-infected T-cell exosomes in lung cancer progression
(PQ1) HIV 感染的 T 细胞外泌体在肺癌进展中的作用
- 批准号:
10656483 - 财政年份:2020
- 资助金额:
$ 75.69万 - 项目类别:
(PQ1) HIV-infected T-cell exosomes in lung cancer progression
(PQ1) HIV 感染的 T 细胞外泌体在肺癌进展中的作用
- 批准号:
10436288 - 财政年份:2020
- 资助金额:
$ 75.69万 - 项目类别:
Oral immune plasticity, HIV-infected T cell extracellular vesicles, and oral cancer
口腔免疫可塑性、HIV感染的T细胞胞外囊泡和口腔癌
- 批准号:
10112750 - 财政年份:2017
- 资助金额:
$ 75.69万 - 项目类别:
Head Neck Cancer, beta-defensins, and immune responses
头颈癌、β-防御素和免疫反应
- 批准号:
9091572 - 财政年份:2015
- 资助金额:
$ 75.69万 - 项目类别:
Head Neck Cancer, beta-defensins, and immune responses
头颈癌、β-防御素和免疫反应
- 批准号:
8942990 - 财政年份:2015
- 资助金额:
$ 75.69万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 75.69万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 75.69万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 75.69万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 75.69万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 75.69万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 75.69万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 75.69万 - 项目类别:














{{item.name}}会员




